Ottawa Hospital Research Institute
ohri.caTotal trials
532
Active
88
Phase 3
49
Total enrollment
2,823,780
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 42 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Apixaban | — | — | — | — | 5 | ||
| Methoxyflurane | — | — | — | — | — | 3 | |
| Rivaroxaban | — | — | — | — | — | 3 | |
| Cephalexin | — | — | — | — | — | 2 | |
| Granulocyte Colony-Stimulating Factor | — | — | — | — | — | 1 | |
| Omission of Granulocyte Colony-Stimulating Factor | — | — | — | — | — | 1 | |
| Bone modifying agent | — | — | — | — | — | 1 | |
| Neomycin and Flagyl | — | — | — | — | — | 1 | |
| Trastuzumab | — | — | — | — | — | 1 | |
| Standard of care administration of Endocrine therapy | — | — | — | — | — | 1 | |
| Dose-frequency escalation administration of Endocrine therapy | — | — | — | — | — | 1 | |
| 20-25% Albumin fluid | — | — | — | — | — | 1 | |
| Rivaroxaban 10 MG | — | — | — | — | — | 3 | |
| Tranexamic Acid | — | — | — | — | 4 | ||
| Prednisone | — | — | — | — | 4 | ||
| Lupron Depot | — | — | — | — | — | 1 | |
| Full dose rivaroxaban | — | — | — | — | — | 1 | |
| Low dose rivaroxaban | — | — | — | — | — | 1 | |
| Rosuvastatin Calcium | — | — | — | — | — | 1 | |
| Colchicine 0.5 mg po | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | — | 1 | |
| Standard of Care | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | — | 1 | |
| Omeprazole 20 mg Oral | — | — | — | — | — | 1 | |
| Triamcinolone Acetonide 40mg/mL | — | — | — | — | — | 1 | |
| Saline | — | — | — | — | — | 1 | |
| Plasma-Lyte A and 25% Autologous Plasma | — | — | — | — | — | 1 | |
| Autologous EPCs | — | — | — | — | — | 1 | |
| Autologous EPCs Transfected with human eNOS | — | — | — | — | — | 1 | |
| Hydroxychloroquine | — | — | — | — | — | 1 | |
| Triptorelin | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | — | — | 1 | |
| Human Allogenic Umbilical Cord Mesenchymal Stromal Cells | — | — | — | — | — | 1 | |
| Cold-stored platelet concentrate | — | — | — | — | — | 1 | |
| Modafinil | — | — | — | — | — | 1 | |
| CLIC-1901 | — | — | — | — | — | 1 | |
| Allogeneic umbilical cord-derived human mesenchymal stromal cells | — | — | — | — | — | 1 | |
| Bupivacaine | — | — | — | 3 | |||
| Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells | — | — | — | — | — | 1 | |
| Phage | — | — | — | — | — | 1 |
2 more active programs hidden
Next readouts
- 2020-03-05
- 2023-11-06
- 2024-07-20
- 2024-07-30
- 2025-01
- 2025-02
- 2025-03-01
- 2025-04-17
- 2025-08-28
- 2025-11-25
Top conditions
- Breast Cancer34
- Cancer20
- Venous Thromboembolism19
- Osteoarthritis15
- Cardiac Arrest12
- Hypertension9
- Surgery8
- Deep Vein Thrombosis8
Frequently asked questions about Ottawa Hospital Research Institute
- How many clinical trials does Ottawa Hospital Research Institute have on ClinicalTrials.gov?
- Ottawa Hospital Research Institute is listed as the lead sponsor on 532 clinical trials in ClinicalTrials.gov, 88 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Ottawa Hospital Research Institute's trials are in Phase 3?
- 49 of Ottawa Hospital Research Institute's trials are in Phase 3, spread across 42 active drug programs.
- What therapeutic areas does Ottawa Hospital Research Institute focus on?
- Ottawa Hospital Research Institute's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Cancer, Venous Thromboembolism, Osteoarthritis, Cardiac Arrest.
- When are Ottawa Hospital Research Institute's next clinical trial readouts?
- Ottawa Hospital Research Institute has 10 upcoming primary-completion readouts tracked here; the soonest is “The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial”, expected around 2020-03-05.